期刊
FEBS JOURNAL
卷 283, 期 22, 页码 4032-4046出版社
WILEY
DOI: 10.1111/febs.13746
关键词
apoptosis; cell cycle arrest; differentiation; histone deacetylase inhibitor; senescence; tumor immunogenicity
资金
- National Health and Medical Research Council of Australia (NHMRC)
- NHMRC Senior Principal Research Fellowship
- Cancer Council Victoria
- Victorian Cancer Agency (VCA)
- Leukaemia Foundation of Australia
- NHMRC
- VCA
- Snowdome Foundation
It is now well recognized that mutations, deregulated expression, and aberrant recruitment of epigenetic readers, writers, and erasers are fundamentally important processes in the onset and maintenance of many human tumors. The molecular, biological, and biochemical characteristics of a particular class of epigenetic erasers, the histone deacetylases (HDACs), have been extensively studied and small-molecule HDAC inhibitors (HDACis) have now been clinically approved for the treatment of human hemopoietic malignancies. This review explores our current understanding of the biological and molecular effects on tumor cells following HDACi treatment. The predominant responses include induction of tumor cell death and inhibition of proliferation that in experimental models have been linked to therapeutic efficacy. However, tumor cell-intrinsic responses to HDACi, including modulating tumor immunogenicity have also been described and may have substantial roles in mediating the antitumor effects of HDACi. We posit that the field has failed to fully reconcile the biological consequences of exposure to HDACis with the molecular events that underpin these responses, however progress is being made. Understanding the pleiotrophic activities of HDACis on tumor cells will hopefully fast track the development of more potent and selective HDACi that may be used alone or in combination to improve patient outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据